B., Malmlf, K., Johansen, P
Notably, DRP-104 demonstrates the ability to counter T cell exhaustion and enhance the functionality of both CD4 + and CD8 + T cells [188]
Key Differences: Regulatory Status and Manufacturing The primary difference between the two lies in the regulatory pathway
Many patients pair it with functional medicine, hormone therapy, or IV therapy as part of a broader plan
Generally, the program is for individuals with a BMI of 30 or higher and excludes those with certain medical conditions, including an eating disorder, active gallbladder disease, specific thyroid cancers, or those who are pregnant or breastfeeding.
This hidden gap can fuel tension, reduce resilience, and make discomfort harder to manage over time